Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02735343 · ClinicalTrials.gov registry record · Phase 3

The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine

A Phase 3 study, sponsored by Mike O'Callaghan Military Hospital.

Terminated
Registry status
Phase 3
Development phase
5
Enrollment target

NCT02735343 is a Phase 3 study that was terminated before completion, run by Mike O'Callaghan Military Hospital. The registered enrollment target is 5 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02735343, a Phase 3 study, was terminated before completion, sponsored by Mike O'Callaghan Military Hospital.

TERMINATED
Registry status
Phase 3
Development phase
5 participants
Enrollment target

Study Summary

Investigators are comparing Ketamine to prochlorperazinecompazine for benign headaches in the ED. Subjects will be randomized into 1 of 2 groups. Group 1 will receive standard treatment of prochlorperazinecompazine 10 mg IV along with diphenhydramine 25 mg IV. Group 2 (research arm) will receive Ketamine 0.3 mg/kg along with ondansetron 4 mg IV. Subjects will be seen at 15, 30, 45, and 60 minutes post-intervention to obtain Heart Rate, Blood Pressure, Headache severity, Nausea severity, Vomiting severity, Anxiety severity, and Restlessness severity. At 24-48 hours post intervention we will contact subjects and assess their pain and assess their satisfaction with their migraine pain management as part of this study. Subjects' participation will last up to 48 hours post headache.

Interventions

  • DRUG Ketamine
  • DRUG Compazine

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2016-08
Est. Completion 2017-05
Phase Phase 3

Sponsor

Mike O'Callaghan Military Hospital

26 total trials

What the Registry Record Tells You About NCT02735343

The ClinicalTrials.gov registry entry for NCT02735343 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mike O'Callaghan Military Hospital, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.

NCT02735343 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02735343 about?

NCT02735343 is a clinical study titled "The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine". Investigators are comparing Ketamine to prochlorperazinecompazine for benign headaches in the ED. Subjects will be randomized into 1 of 2 groups. Group 1 will receive standard treatment of prochlorperazinecompazine 10 mg IV along with diphenhydramine 25 mg IV. Group 2 (research arm) will receive Ket...

What is the current status of trial NCT02735343?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2016-08. Estimated completion is 2017-05.

What interventions are being tested in trial NCT02735343?

The interventions under investigation include: Ketamine (DRUG), Compazine (DRUG).

Who is sponsoring clinical trial NCT02735343?

This trial is sponsored by Mike O'Callaghan Military Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.